Shionogi’s oral antiviral for respiratory syncytial virus (RSV) has met its primary endpoint in a Phase II study that saw some participants achieving an 88.94% reduction in viral load. The Japanese ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback